PHILADELPHIA, October 02, 2025--iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo ...
Treatment with the IL-23 inhibitor significantly improved skin clearance in the pediatric study of children aged 6-17 with ...
Dell Children's doctors track development, offer therapy and study which NICU treatments lead to the best long-term outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback